About AVT
Browse Articles
Customer Services


Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule

Christopher B Hurt

Corresponding author name: Christopher B Hurt
Corresponding author e-mail: christopher_hurt@med.unc.edu

Citation: Antiviral Therapy 2011; 16:137-140
doi: 10.3851/IMP1750

Date accepted: 21 January 2010
Date published online: 04 March 2011


Transmitted drug resistance (TDR), the primary acquisition of an HIV variant already resistant to antiretrovirals, affects approximately 15% of all new infections in the United States.

Historically, from the time initial agents in the reverse transcriptase, protease and entry inhibitor classes were introduced, it took 3–5 years before the first case reports of TDR appeared. With the description of the first two cases of transmitted integrase stand-transfer inhibitor resistance, it is only a matter of time before the prevalence of TDR affecting this newest antiretroviral class reaches a level warranting baseline resistance testing for all patients entering care.


Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.